Immunization of mice by a multimeric L2-based linear epitope (17-36) from HPV type 16/18 induced cross reactive neutralizing antibodies.

about

A Dual-Type L2 11-88 Peptide from HPV Types 16/18 Formulated in Montanide ISA 720 Induced Strong and Balanced Th1/Th2 Immune Responses, Associated with High Titers of Broad Spectrum Cross-Reactive Antibodies in Vaccinated Mice.

P2860

Q55215825-9A004EFA-CC1C-411E-A65E-599EC0291E23

P2860

Immunization of mice by a multimeric L2-based linear epitope (17-36) from HPV type 16/18 induced cross reactive neutralizing antibodies.

Item

http://www.wikidata.org/entity/Q40064084

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Immunization of mice by a mult ...... ctive neutralizing antibodies.

@en

type

Item

label

Immunization of mice by a mult ...... ctive neutralizing antibodies.

@en

prefLabel

Immunization of mice by a mult ...... ctive neutralizing antibodies.

@en

P1476

Immunization of mice by a mult ...... active neutralizing antibodies

@en

P2093

Farhad Motavalli Khiavi

http://www.w3.org/2001/XMLSchema#string

Farzin Roohvand

http://www.w3.org/2001/XMLSchema#string

Majid Golkar

http://www.w3.org/2001/XMLSchema#string

Maryam Nasimi

http://www.w3.org/2001/XMLSchema#string

P2860

The Prevalence of Cervical Human Papillomavirus Infection and the Most At-risk Genotypes Among Iranian Healthy Women: A Systematic Review and Meta-analysis

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines

Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes

Epidemiologic classification of human papillomavirus types associated with cervical cancer

A vaccine of L2 epitope repeats fused with a modified IgG1 Fc induced cross-neutralizing antibodies and protective immunity against divergent human papillomavirus types.

Optimization of multimeric human papillomavirus L2 vaccines.

A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies.

Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2.

A protective and broadly cross-neutralizing epitope of human papillomavirus L2.

P304

265-273

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/1735-5362.212043

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Kayhan Azadmanesh

Mehdi Mahdavi

Arash Arashkia

P577

2017-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28855937

http://www.w3.org/2001/XMLSchema#string

P932

5566000

http://www.w3.org/2001/XMLSchema#string

Immunization of mice by a multimeric L2-based linear epitope (17-36) from HPV type 16/18 induced cross reactive neutralizing antibodies.

about

P2860

P2860

Immunization of mice by a multimeric L2-based linear epitope (17-36) from HPV type 16/18 induced cross reactive neutralizing antibodies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932